Companies researching Skyrizi (Risankizumab)
Skyrizi (risankizumab) is a humanized monoclonal antibody that inhibits interleukin‑23A and is jointly developed by Boehringer Ingelheim and AbbVie for treating plaque psoriasis.
13
companies
List of companies that research Skyrizi (Risankizumab)
This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →
| Company | Country | Industry | Employees | Revenue | Technologies |
|---|---|---|---|---|---|
 United States | Pharmaceutical Manufacturing | 63k | $26B | Skyrizi (Risankizumab) | |
United States | Hospitals and Health Care | 269 | $25M | Skyrizi (Risankizumab) | |
United States | Hospitals and Health Care | 317 | Skyrizi (Risankizumab) | ||
United States | Hospitals and Health Care | 501 | $100M | Skyrizi (Risankizumab) | |
United States | Hospitals and Health Care | 1k | Skyrizi (Risankizumab) | ||
United States | Hospitals and Health Care | 201 | $12M | Skyrizi (Risankizumab) |
Showing top companies out of 13 that research Skyrizi (Risankizumab). Get the full list on TheirStack.
Frequently asked questions